Global life sciences company Pressure BioSciences (OTCQB: PBIO) was recently highlighted in a release by The Ohio State University detailing the university’s upcoming study regarding healthier food and beverage options. Per the news release, a team of scientists from Ohio State’s College of Food, Agricultural, and Environmental Sciences (“CFAES”) has been awarded a four-year, $891,000 … Continue reading “NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Collaborates with Ohio State University to Study Ultra-Shear Technology”
Global life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) recently announced a debt-to-equity swap, resulting in a total loan debt amount that company management sees as manageable. An article further discussing the company reads: “Pressure BioSciences Inc.’s (OTCQB: PBIO) ambitions to achieve listing on a major stock exchange this year have taken another major step … Continue reading “NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Recent Equity Swap Boosts Plans to Uplist”
Global life sciences company Pressure BioSciences Inc.’s (OTCQB: PBIO) president and CEO Richard T. Schumacher was recently interviewed on Uptick Newswire’s “Stock Day” podcast. Among other highlights of the interview, Schumacher discussed the company’s sustained financial success, the noteworthy amount of debt it has converted into equity over the past 30 days, and upcoming plans … Continue reading “NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) President and CEO Discusses Recent Company Activities in Interview on Uptick Newswire’s “Stock Day” Podcast”
Equity swap further boosts Pressure BioSciences’ plans to uplist to a major stock exchange later this year Latest deal brings total debt-to-equity conversions to over $13.6M in past 30 days 2015/2016 debentures, line-of-credit and promissory note, plus various short-term debt, now converted to equity Company’s recently acquired Pre-EMT™ platform, allowing for improved protein-based drug development, … Continue reading “Pressure BioSciences, Inc. (PBIO) Announces $7.24M Debt-to-Equity Swap as it Prepares for 2018 Uplisting to National Stock Exchange”
Global life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) this morning announced the conversion of an additional $7.24 million of debt into equity, bringing the total amount of debt that has converted into equity over the past four weeks to $13.6 million. “With today’s announced conversion of an additional $7.24M of debt to equity, total … Continue reading “NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Conversion of Additional $7.24M of Debt into Equity”
Global life sciences company Pressure BioSciences (OTCQB: PBIO) recently acquired the PreEMT™ platform to develop a unique manufacturing method and improve the quality of a key protein-based drug being developed. A recent article discussing the company reads: “The acquisition of the PreEMT technology gives PBIO a footprint in the very large and growing biologics contract … Continue reading “NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Boosts Drug Development Process through Acquisition of PreEMT™ Platform”
Biologics offer novel ways of treating degenerative diseases like Alzheimer’s Biologics are one of the fastest-growing drug categories PreEMT™ technology improves quality, reduces cost of biologic manufacture When we think of drugs, an image of potions in round-bottom flasks conjured up in labs comes to mind, or perhaps pills of one sort or another ingested … Continue reading “Pressure BioSciences Inc.’s (PBIO) Recently Acquired PreEMT™ Platform Enhances Development of Biotherapeutic Protein Drugs”
Global life sciences company Pressure BioSciences (OTCQB: PBIO) recently announced financial results for the first quarter ended March 31, 2018. Among other highlights, the company reported first quarter revenue growth and debenture conversion. An article discussing the report further reads: “The first quarter of 2018 was the ninth consecutive quarter in which the company reported … Continue reading “NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Reports Increase in Revenue, Debt Conversion in Q1 2018”
High-pressure lab equipment maker reports ninth consecutive quarter of revenue growth (Y/Y) About 92 percent of debenture debt converted to preferred stock, with aim of uplisting to national stock exchange Patented technologies continue to drive optimism for company’s products to enhance and improve scientific research Pressure BioSciences, Inc. (OTCQB: PBIO), the maker of a patented … Continue reading “Revenue Growth, Debt Conversion Boost Pressure BioSciences’ (PBIO) Outlook at Close of First Quarter”
Global life sciences company Pressure BioSciences (OTCQB: PBIO) today announced financial results for the first quarter ended March 31, 2018. Among other highlights, Pressure BioSciences reported total revenue of $610,774 for the first quarter of 2018 compared to $551,357 for the same period in 2017, demonstrating an increase of 11%. The company attributes the increase … Continue reading “NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Reports Q1 Financial Results, Provides Business Update; Schedules Earnings Call”
